Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer.
作者信息
Nardin Simone, Del Mastro Lucia
机构信息
U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Department of Internal Medicine and Medical Sciences (DiMI), School of Medicine, University of Genova, Genova, Italy.
出版信息
Ann Transl Med. 2023 Mar 15;11(5):228. doi: 10.21037/atm-22-6266. Epub 2023 Jan 9.
Abstract
摘要
相似文献
1
Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer.
Ann Transl Med. 2023 Mar 15;11(5):228. doi: 10.21037/atm-22-6266. Epub 2023 Jan 9.
2
Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
Future Oncol. 2022 Sep;18(28):3199-3215. doi: 10.2217/fon-2022-0407. Epub 2022 Sep 7.
3
A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative).
Future Oncol. 2024 Apr;20(11):635-651. doi: 10.2217/fon-2023-0845. Epub 2024 Jan 25.
4
Sacituzumab govitecan for hormone receptor-positive and triple-negative breast cancers.
Mol Cell Pharmacol. 2023;15(1):1-5.
5
Tackling metastatic triple-negative breast cancer with sacituzumab govitecan.
Expert Rev Anticancer Ther. 2021 Dec;21(12):1303-1311. doi: 10.1080/14737140.2021.1993065. Epub 2021 Oct 22.
6
Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan.
Expert Opin Biol Ther. 2021 Jul;21(7):903-913. doi: 10.1080/14712598.2021.1840547. Epub 2020 Dec 27.
7
Antibody-Drug Conjugates in HR+ Breast Cancer: Where Are We Now and Where Are We Heading?
J Clin Med. 2023 Nov 26;12(23):7325. doi: 10.3390/jcm12237325.
8
Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
Expert Rev Anticancer Ther. 2019 Aug;19(8):673-679. doi: 10.1080/14737140.2019.1654378. Epub 2019 Aug 19.
9
Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report.
Front Oncol. 2023 Feb 20;13:1139372. doi: 10.3389/fonc.2023.1139372. eCollection 2023.
10
Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities.
Oncologist. 2021 Oct;26(10):827-834. doi: 10.1002/onco.13878. Epub 2021 Jul 10.
引用本文的文献
1
Efficacy and safety of Sacituzumab govitecan in solid tumors: a systematic review and meta-analysis.
Front Oncol. 2025 Jun 20;15:1624386. doi: 10.3389/fonc.2025.1624386. eCollection 2025.
2
The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2- Breast Cancer: A Multicenter Observational Study from Turkey.
Cancers (Basel). 2025 May 7;17(9):1592. doi: 10.3390/cancers17091592.
3
Types and progress of clinical trial design for breast cancer: a narrative review.
Transl Breast Cancer Res. 2023 Jul 30;4:20. doi: 10.21037/tbcr-23-22. eCollection 2023.
本文引用的文献
1
Current and future burden of breast cancer: Global statistics for 2020 and 2040.
Breast. 2022 Dec;66:15-23. doi: 10.1016/j.breast.2022.08.010. Epub 2022 Sep 2.
2
Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
J Clin Oncol. 2022 Oct 10;40(29):3365-3376. doi: 10.1200/JCO.22.01002. Epub 2022 Aug 26.
3
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5.
4
Antibody-drug conjugates in HER2-positive breast cancer.
Chin Med J (Engl). 2021 Dec 22;135(3):261-267. doi: 10.1097/CM9.0000000000001932.
5
Antibody-Drug Conjugates for Breast Cancer.
Oncol Res Treat. 2022;45(1-2):26-36. doi: 10.1159/000521499. Epub 2021 Dec 16.
6
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.
Ann Oncol. 2021 Dec;32(12):1475-1495. doi: 10.1016/j.annonc.2021.09.019. Epub 2021 Oct 19.
7
Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
J Clin Oncol. 2021 Dec 10;39(35):3959-3977. doi: 10.1200/JCO.21.01392. Epub 2021 Jul 29.
8
Antibody-Drug Conjugates for the Treatment of Breast Cancer.
Cancers (Basel). 2021 Jun 9;13(12):2898. doi: 10.3390/cancers13122898.
9
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors.
J Clin Oncol. 2021 Aug 1;39(22):2474-2485. doi: 10.1200/JCO.20.03489. Epub 2021 Apr 30.
10
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485.
Zotero 插件